Biphenyl

Biphenyl

SCHEMBL2192409

N.O=S(=O)(O)C(F)(F)F.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.56
PTPN5 P54829 2/20 0.45
KIF11 P52732 1/20 0.44
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
CA12 O43570 1/20 0.41
CA5A P35218 1/20 0.40
MMP2 P08253 1/20 0.39
MMP7 P09237 1/20 0.39
MMP14 P50281 1/20 0.39
HDAC6 Q9UBN7 2/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL1050411 0.98 PTPN1 (0.58) PTPN1PTPN5KIF11ALDH1A1TSHR
Biphenyl SCHEMBL304392 0.95 PTPN1 (0.56) PTPN1PTPN5KIF11ALDH1A1TSHR
Biphenyl SCHEMBL5410059 0.95 PTPN1 (0.56) PTPN1PTPN5KIF11ALDH1A1TSHR
Biphenyl SCHEMBL27838332 0.91 PTPN1 (0.53) PTPN1PTPN5KIF11ALDH1A1TSHR
Trifluoromethanesulfonic Acid SCHEMBL31473545 0.86 PTPN1 (0.53) PTPN1PTPN5KIF11CA1CA2
Trifluoromethanesulfonic Acid SCHEMBL27707915 0.86 PTPN1 (0.53) PTPN1PTPN5KIF11CA1CA2
Biphenyl SCHEMBL30131105 0.84 PTPN1 (0.47) PTPN1PTPN5KIF11ALDH1A1TSHR
Trifluoromethanesulfonic Acid SCHEMBL27826316 0.82 TSHR (0.48) PTPN1ALDH1A1TSHRSMN1; SMN2CA1
Trifluoromethanesulfonic Acid SCHEMBL789189 0.82 ALDH1A1 (0.50) PTPN1ALDH1A1TSHRSMN1; SMN2CA1
Trifluoromethanesulfonic Acid SCHEMBL30552135 0.82 ALDH1A1 (0.50) PTPN1ALDH1A1TSHRSMN1; SMN2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324891-A1 COMPOSITIONS AND METHODS FOR PREPARING REGIO- AND STEREOSELECTIVE ALICYCLIC ALKENE ISOTOPOLOGUES AND STEREOISOTOPOMERS UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2022-10-13 US disclosed
WO-2020257299-A1 COMPOSITIONS AND METHODS FOR PREPARING REGIO- AND STEREOSELECTIVE ALICYCLIC ALKENE ISOTOPOLOGUES AND STEREOISOTOPOMERS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2020-12-24 WO disclosed
US-20190247354-A1 CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2019-08-15 US disclosed
US-10206897-B2 Creatine ester anti-inflammatory compounds and formulations BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2019-02-19 US disclosed
US-20180153844-A1 CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2018-06-07 US disclosed
US-9833427-B2 Creatine ester anti-inflammatory compounds and formulations BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2017-12-05 US disclosed
US-20170202241-A1 CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2017-07-20 US disclosed
CN-105368029-A Polymer compositions and method NOVOMER INC 2016-03-02 CN disclosed
CN-102026954-B Processes for the preparation of esters SYNGENTA PARTICIPATIONS AG 2014-06-04 CN disclosed
US-20120289648-A1 REACTIVE COMPOUNDS ON THE BASIS OF TRANSESTERIFICATION EVONIK DEGUSSA GMBH (DE) 2012-11-15 US disclosed
US-20070203076-A1 CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS VENNERSTROM JONATHAN L 2007-08-30 US disclosed
CN-101003591-A Resin suitable for an acid generator and a chemically amplified positive resist composition containing the same SUMITOMO CHEMICAL CO (JP) 2007-07-25 CN disclosed
EP-1324760-B1 CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS UNIV NEBRASKA (US) 2007-06-20 EP disclosed
EP-1688139-A1 Creatine ester pronutrient compounds and formulations Board of Regents of the University of Nebraska (US) 2006-08-09 EP disclosed
EP-1324760-A4 CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS REGENTS OFTHE UNIVERSITY OF NE (US) 2005-08-10 EP disclosed
WO-2004071406-A2 CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2004-08-26 WO disclosed
US-20030212130-A1 Creatine ester anti-inflammatory compounds and formulations NEBRASKA, UNIVERSITY OF MEDICAL CENTER 2003-11-13 US disclosed
US-20030212136-A1 Creatine ester pronutrient compounds and formulations BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2003-11-13 US disclosed
EP-1324760-A1 CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS Board of Regents of the University of Nebraska (US) 2003-07-09 EP disclosed
WO-2002022135-A1 CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212130-A1 Creatine ester anti-inflammatory compounds and formulations CKMT1A; CKMT1B, CPT1B, CRAT PTPN1 4574/4885PTPN5 4391/4885KIF11 2753/4885
US-20180153844-A1 CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS CKMT1A; CKMT1B, CPT1B, CRAT PTPN1 4574/4885PTPN5 4391/4885KIF11 2753/4885
US-20190247354-A1 CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS CKMT1A; CKMT1B, CPT1B, CRAT PTPN1 4574/4885PTPN5 4391/4885KIF11 2753/4885
US-20170202241-A1 CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS CKMT1A; CKMT1B, CPT1B, PYGM PTPN1 4844/4885PTPN5 4770/4885KIF11 1261/4885
US-10206897-B2 Creatine ester anti-inflammatory compounds and formulations CKMT1A; CKMT1B, CPT1B, CRAT PTPN1 4574/4885PTPN5 4391/4885KIF11 2753/4885
US-20070203076-A1 CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS CKMT1A; CKMT1B, CPT1B, PYGM PTPN1 4844/4885PTPN5 4770/4885KIF11 1261/4885
US-20030212136-A1 Creatine ester pronutrient compounds and formulations CKMT1A; CKMT1B, CPT1B, PYGM PTPN1 4829/4885PTPN5 4736/4885KIF11 1417/4885
US-20220324891-A1 COMPOSITIONS AND METHODS FOR PREPARING REGIO- AND STEREOSELECTIVE ALICYCLIC ALKENE ISOTOPOLOGUES AND STEREOISOTOPOMERS ADRA2C, HTR2C, HTR1B PTPN1 3614/4885PTPN5 3940/4885KIF11 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.